Janus Henderson Short Duration Income ETF (ARCA: VNLA)

Latest News for Janus Henderson Short Duration Income ETF (ARCA:VNLA)

Janus Henderson Short Duration Income ETF

Janus Short Duration Income ETF

Vanilla Network

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold.

News

Reiteration

Analyst Ratings

GMED

Needham Reiterates Hold on Globus Medical

Greystone Housing Impact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHI#NYSE">GHI</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.24 by 75 percent. This is a 28.81 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $22.371 million which missed the analyst consensus estimate of $24.332 million by 8.06 percent. This is a 10.29 percent decrease over sales of $24.938 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Greystone Housing Impact Q1 2024 GAAP EPS $0.42 Beats $0.24 Estimate, Sales $22.371M Miss $24.332M Estimate

ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1.05) by 33.33 percent.

AVBP

ArriVent BioPharma Q1 EPS $(0.70) Beats $(1.05) Estimate

Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Neutral and raises the price target from $117 to $126.

Price Target

MASI

Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and lowers the price target from $33 to $27.

VCYT

Needham Maintains Buy on Veracyte, Lowers Price Target to $27

Assumes leadership role as Company anticipates multiple near-term clinical milestones &nbsp;
Brings extensive leadership and experience in drug development and business strategy
LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021.
Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Study with IMUNON's lead asset, IMNN-001 using the TheraPlas modality, in advanced ovarian cancer are expected by mid-summer. Phase 1 proof-of-concept data from IMNN-101 using the PlaCCine modality in seasonal COVID-19 are anticipated by year-end.
"Dr. Lindborg is uniquely qualified to take the reins as IMUNON's President and CEO, bringing a track record of success in virtually every aspect of the work before the company," said Michael H. Tardugno, IMUNON's executive chairman. "Her ability to navigate global regulatory paths, having successfully delivered products from the clinic to the market, will be valuable to IMUNON as our pipeline advances. We have benefited significantly from her counsel as a director, where she has played an integral role in establishing our strategic priorities. We now look forward to benefiting from her expertise in a new and deeper capacity, especially as our near-term data readouts will require important decisions with respect to advancing various programs and assets."
Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&amp;D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. She joins IMUNON from BrainStorm Cell Therapeutics, where she was Executive Vice President and Co-Chief Executive Officer and where she remains a member of the board of directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.
Dr. Lindborg previously was Vice President &amp; Global Analytics and Data Sciences Head, responsible for R&amp;D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&amp;D strategy.
Commenting on her appointment, Dr. Lindborg said, "I have enjoyed being close to the emerging science during the development of our IL-12 therapy TheraPlas and our PlaCCine modalities, in addition to getting to know the depth of talent in the company. I am thrilled to assume direct managerial responsibilities as we work to bring these important products and technologies to patients. I am also excited by the prospect of creating shareholder value as we determine the next steps for our platform products."
Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

Management

IMNN

IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial―
― Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q'24―
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.&#xAE;&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD). The data are published in the peer-reviewed journal <a href="https://www.globenewswire.com/Tracker?data=ACUOiZ0Tt4jkkYIUGdTjoKSFf0xuJqPYgp-2RVOih9lao3lpHGrNl1R4Q2K68TwG7-6bWZGHLBrKRfheAiJP82-0Q6h1wiA8LcKKC_h9j2loCjJvK9KuW3t_yopNL_O4MJeGaxL7PZu19wDxQCBVOFqOfdylZGnr9Jdrw3W1ubc=">The Lancet Neurology</a>.
FSHD is a serious, rare, and progressively disabling disease characterized by fat infiltration of skeletal muscle leading to muscular atrophy involving primarily the face, shoulder girdle, upper arms, abdomen, and lower limbs. It is caused by the aberrant expression of the DUX4 protein. It is characterized by accumulating muscle weakness and functional impairment. There are no approved disease-modifying treatments for FSHD.
"The publication of these results, which informed the design and choice of efficacy endpoints in our Phase 3 clinical trial, also provide important validation for the therapeutic potential of losmapimod," said Patrick Horn M.D., Ph.D., Fulcrum's chief medical officer. "Looking ahead, we remain on track to report topline data for REACH in the fourth quarter of 2024, which will bring us one step closer to addressing the high unmet needs of the FSHD patient community. With an unwavering commitment to our patients, we continue to take important steps toward a potential NDA filing and commercial launch for losmapimod."

Biotech

General

FULC

Fulcrum Therapeutics Announces Publication Of Results From Phase 2b Clinical Trial Of Losmapimod In Facioscapulohumeral Muscular Dystrophy In The Lancet Neurology

Piper Sandler analyst Brian Mullan maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Neutral and lowers the price target from $81 to $67.

JACK

Piper Sandler Maintains Neutral on Jack In The Box, Lowers Price Target to $67

Ongoing partnership and third order underscores confidence in Cognyte solutions
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cognyte.com%2F&amp;esheet=53976993&amp;newsitemid=20240508670666&amp;lan=en-US&amp;anchor=Cognyte+Software+Ltd&amp;index=1&amp;md5=59a27beb66af5a3d08aad290cbadc592">Cognyte Software Ltd</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) ("Cognyte"), a global leader in investigative analytics software, today announced that it received an approximately $5 million additional order from a national intelligence organization in the Europe-Middle East-Africa (EMEA) region, for its solution that helps identify and prevent threats during operations.
Including this latest order, Cognyte has received three orders from this customer over the past year, serving as a testament to the superiority of the company's technology. Through ongoing delivery of effective results, Cognyte's solutions enhance operational efficiency and create substantial value for the customer's operational teams.
"We have consistently delivered value to this customer with solutions that align to their evolving needs," said Efi Nuri, Cognyte's chief revenue officer. "The effectiveness of our technology, coupled with our ability to provide solutions that address the growing challenges our global customers face, continues to open opportunities for driving growth. We are pleased to expand our partnership with this customer and look forward to further collaboration."

Contracts

CGNT

Cognyte Secures ~$5M Follow-On Order With National Intelligence Organization

EV truck maker Nikola Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) saw the average sales price of its fuel cell electric vehicle (FCEV) trucks rise by $30,000 in the first quarter as compared to the prior quarter, contrary to other EV makers who have been witnessing their vehicle prices fall amid a severe price war. However, going forward, the company intends to be &#8220;flexible&#8221; with its pricing. 
Average Selling Price Rise: The average sales price of the company&#8217;s fuel cell truck rose to $381,000 in the first quarter, company CEO Steve Girsky said on Tuesday during the company&#8217;s first-quarter earnings call. 
Future Plan Outline: The company is currently looking to build volume across North America to optimize its cost structure. The focus, the CEO said, would be on selling to fleets with over 1000 trucks and selling outside of its focus areas of California and Canada. While California and Canada have the best incentives for EV makers at this point in time, other states are starting to offer incentives of their own, Girsky noted. 
While the company does not intend to cut prices, it would be &#8220;flexible&#8221; with the initial part of its deal to large fleet operators, he said. 
&#8220;We&#8217;re just not going to walk away from a great deal with a great customer because we&#8217;re being too stingy on price,&#8221; company CFO Tom Okray said while adding that bigger customers generally get better price deals than smaller customers. 
The price per unit in the next quarter would vary depending on customers, Okray said. 
&#8220;At this point, it depends, again, on the order book and what&#8217;s the mix between the bigger fleet customers and the smaller fleet customers and then the much smaller fleets. All of those will have different pricing and a different economic profile. And again, I could throw out a number, and it would probably be wrong,&#8221; Okray said when asked about the expected price per unit in Q2.
Nikola Financials: Nikola<a href="https://www.benzinga.com/news/earnings/24/05/38672379/ev-truck-maker-nikolas-topline-plunges-30-in-q1-on-weak-demand-stock-tanks"> wholesaled 40 fuel cell trucks in the first quarter</a> and produced 43 trucks. The company reported total revenue of $7.5 million in the quarter and a net loss of $147.7 million, down from the $169.1 million reported in the corresponding quarter last year. 
Price Action: Nikola stock fell 5.4% on Tuesday at $0.6. The stock is down nearly 27% year-to-date, according to data from<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/05/38694651/rivian-aims-to-churn-out-215k-evs-from-illinois-factory-with-r2-leading-charge-and-save-over-2b">Rivian Aims To Churn Out 215K EVs From Illinois Factory, With R2 Leading Charge, And Save Over $2B</a>
 Photo courtesy: Nikola

Tech

NKLA

Nikola Open To 'Flexible' Pricing For Large Fleet Deals As EV Truck Maker Fishes For Bigger Customers Outside California

FRSX

Foresight Highlights Use Of NVIDIA Jetson AGX Orin System

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected &nbsp;
IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of its ex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be presented today at an oral presentation during the American Society of Cell &amp; Gene Therapy 27th Annual Meeting in Baltimore. Prime Medicine recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for PM359 for the treatment of CGD.
"These data are incredibly exciting—showing for the first time that Prime Editing can not only correct the disease-causing mutation of CGD in human blood stem cells, but that those cells can produce neutrophils with restored immune function and healthy activity following engraftment in rodents with no off-target edits observed," said Jennifer Gori, Ph.D., Vice President, Head of Hematology and Immunology at Prime Medicine. "Further, we were able to demonstrate clinical-scale production of Prime Edited blood stem cells, supporting our planned advancement into the clinic with PM359."
CGD is a rare inherited disease that leads to recurrent, debilitating and often life-threatening infections. CGD is caused by mutations in any one of the subunits comprising the NADPH oxidase complex, an enzyme that kills bacteria and fungi to control infection. CGD causative mutations are estimated to occur in between one in 100,000 and one in 200,000 births in the U.S., and most children are diagnosed within the first three years of life. The second most common form of CGD, which represents approximately 25% of cases, is caused by loss-of-function mutations in both copies of the NCF1 gene encoding the p47phox protein.
Prime Medicine is advancing an ex vivo Prime Editing program, PM359, that aims to correct the predominant mutation in NCF1 in CGD patient CD34+ hematopoietic stem cells (HSCs) and restore NADPH oxidase function.
In today's presentation at ASGCT, Prime Medicine highlighted data from a series of in vivo non-clinical studies using human CGD patient CD34+ HSCs. Notably, findings demonstrated restoration of neutrophil function after stem cell engraftment in mice, as well as the ability to scale up production of Prime Edited cells to clinical scale. Detailed findings are as follows:
<ul>
<li>Prime Editing precisely corrected the CGD causative mutation in greater than 75% of CGD patient CD34+ cells</li>
<li>The CGD causative mutation is corrected in ≧80% Prime Edited CGD patient CD34+ cells that engraft the bone marrow in a mouse model</li>
<li>NADPH oxidase activity was restored in bone marrow neutrophils in the mice engrafted with Prime Edited CGD patient CD34+ cells</li>
<li>Interferon-regulated gene expression in Prime Edited CGD patient cells was reduced compared to unedited CGD patient cells and similar to healthy donor cells, suggesting Prime Editing restored cells to healthy state</li>
<li>No unintended or off-target edits were detected in engrafted Prime Edited CGD patient CD34+ cells</li>
<li>Process development supported reproducible and efficient manufacturing of clinical-scale healthy donor drug products (HDDP) with high purity, viability, potency and Prime Editing efficiency
<ul>
<li>Long-term engraftment of HDDP was achieved with human multilineage blood production and biodistribution maintained &nbsp;</li>
</ul>
</li>
</ul>
"We are very pleased to report these data from our PM359 program in CGD, which supported the basis of our IND application package to the U.S. FDA," said Jeremy Duffield, M.D., Ph.D., Chief Scientific Officer of Prime Medicine. "With our recent IND clearance, we are working efficiently to move forward with our Phase 1/2 clinical trial of PM359, from which we expect to report first-in-human data in 2025. This is a significant moment for Prime Medicine and the gene editing field, and I am grateful for the unwavering commitment of my colleagues to advance this program. I look forward to the planned evaluation of PM359 in the clinic so that we can truly realize the impact this novel technology may have on patients in need of new treatments."

PRME

Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

Piper Sandler analyst Adam Maeder maintains Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and raises the price target from $250 to $255.

INSP

Piper Sandler Maintains Overweight on Inspire Medical Systems, Raises Price Target to $255

TGNA

TEGNA Sees Q2 Total Company GAAP Revenue Of Down Low-To-Mid Single Digit Percent, With Total Non-GAAP Operating Expenses Flat Year Over year

HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) reported quarterly losses of $(0.01) per share. This is a 90.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported $295.65 million in sales this quarter. This is a 0.61 percent increase over sales of $293.86 million the same period last year.

HFFG

HF Foods Group Q1 GAAP EPS $(0.01) Up From $(0.11) YoY, Sales $295.65M Up From $293.86M YoY

IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.20) by 55 percent. This is a 1650 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $8.95 million which missed the analyst consensus estimate of $10.60 million by 15.58 percent. This is a 8.16 percent decrease over sales of $9.74 million the same period last year.

IMCC

IM Cannabis Q1 EPS $(0.31) Misses $(0.20) Estimate, Sales $8.95M Miss $10.60M Estimate

New solution within Oracle Cloud HCM helps leadership teams maximize talent potential and align upskilling with business priorities
AUSTIN, Texas, May 8, 2024 /PRNewswire/ --&nbsp;Oracle today announced a new AI-powered upskilling solution within <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4161312-1&amp;h=2360551663&amp;u=https%3A%2F%2Fwww.oracle.com%2Fhuman-capital-management%2Femployee-experience%2Foracle-me%2Fgrow%2F&amp;a=Oracle+Grow">Oracle Grow</a>, part of the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4161312-1&amp;h=689495897&amp;u=https%3A%2F%2Fwww.oracle.com%2Fhuman-capital-management%2Femployee-experience%2Foracle-me%2F&amp;a=Oracle+ME+employee+experience+platform">Oracle ME employee experience platform</a> within <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4161312-1&amp;h=260780166&amp;u=https%3A%2F%2Fwww.oracle.com%2Fhuman-capital-management%2F&amp;a=Oracle+Fusion+Cloud+Human+Capital+Management+(HCM)">Oracle Fusion Cloud Human Capital Management (HCM)</a>. Oracle Grow for Business Leaders supports employee development and strengthens organizational agility by helping business leaders quickly develop, upskill, and empower their teams to better achieve business outcomes.
"Today's fast-paced market has created a continuously moving target around business outcomes and the skills needed to achieve them. To maximize talent potential and business success in this environment, business leaders need the tools to upskill their teams quickly and efficiently," said Chris Leone, executive vice president, applications development, Oracle. "Oracle Grow for Business Leaders addresses this need and gives business leaders the ability to find the right people and successfully align skills and business strategy."

ORCL

Oracle's New AI-Powered Skills Solution Helps Organizations Drive Employee And Business Growth

Mizuho analyst Uy Ear maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Neutral and lowers the price target from $7 to $6.

QURE

Mizuho Maintains Neutral on uniQure, Lowers Price Target to $6

Anheuser-Busch InBev SA/NV&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) shares are trading higher after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38690874/ab-inbev-reports-first-quarter-2024-results" rel="noreferrer noopener">reported better-than-expected first-quarter FY24 earnings.</a>
The company reported first-quarter FY24 sales growth of 2.6% organically year-on-year to $14.547 billion, beating the analyst consensus estimate of $14.416 billion.
On&nbsp;Organic&nbsp;basis, total volumes declined by 0.6%, with&nbsp;own beer&nbsp;volumes down by 1.3% and non-beer volumes up by 3.5%.&nbsp;Revenue per hl grew 3.3%.
Gross profit expanded 2.7% organically to $7.89 billion, and gross margin expanded marginally to 54.3%.
Normalized EBITDA for the quarter grew 5.4% organically&nbsp;to $4.9 billion, with the margin expanding 90 basis points to 34.3%.
Underlying profit for the quarter was $1.509 billion compared to $1.31 billion last year. Underlying EPS of $0.75 <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beat the consensus estimate of $0.67.</a>
&#8220;The strength of the beer category, our diversified global footprint and the continued momentum of our megabrands delivered another quarter of broad-based top- and bottom-line growth,&#8221; said CEO Michel Doukeris.
Outlook: Anheuser-Busch InBev expects its FY24 EBITDA to grow in line with its medium-term outlook of 4%-8%. It expects FY24 capital expenditure of <a href="https://www.benzinga.com/calendars/guidance">$4 billion &#8211; $4.5 billion.</a>
Price Action: BUD shares are trading higher by 4.84% at $63.50 in premarket at the last check Wednesday.
Image: Bud Light and Budweiser via Shutterstock